John A. Roberts Acquires 12,200 Shares of Cancer Genetics Inc (CGIX) Stock

Cancer Genetics Inc (NASDAQ:CGIX) COO John A. Roberts bought 12,200 shares of the company’s stock in a transaction that occurred on Friday, December 15th. The shares were purchased at an average price of $2.00 per share, with a total value of $24,400.00. Following the transaction, the chief operating officer now directly owns 12,200 shares in the company, valued at $24,400. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Shares of Cancer Genetics Inc (NASDAQ CGIX) opened at $1.95 on Monday. Cancer Genetics Inc has a fifty-two week low of $1.30 and a fifty-two week high of $5.30. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.01 and a quick ratio of 2.01.

A number of large investors have recently modified their holdings of the business. Northern Trust Corp grew its holdings in Cancer Genetics by 61.0% during the 2nd quarter. Northern Trust Corp now owns 32,122 shares of the medical research company’s stock worth $127,000 after acquiring an additional 12,168 shares during the last quarter. Granahan Investment Management Inc. MA grew its holdings in Cancer Genetics by 26.3% during the 3rd quarter. Granahan Investment Management Inc. MA now owns 237,431 shares of the medical research company’s stock worth $641,000 after acquiring an additional 49,371 shares during the last quarter. Thompson Davis & CO. Inc. grew its holdings in Cancer Genetics by 5,465.0% during the 2nd quarter. Thompson Davis & CO. Inc. now owns 111,300 shares of the medical research company’s stock worth $440,000 after acquiring an additional 109,300 shares during the last quarter. Renaissance Technologies LLC grew its holdings in Cancer Genetics by 44.8% during the 1st quarter. Renaissance Technologies LLC now owns 449,600 shares of the medical research company’s stock worth $1,843,000 after acquiring an additional 139,200 shares during the last quarter. Finally, Vanguard Group Inc. grew its holdings in Cancer Genetics by 61.9% during the 2nd quarter. Vanguard Group Inc. now owns 516,785 shares of the medical research company’s stock worth $2,041,000 after acquiring an additional 197,619 shares during the last quarter. 12.71% of the stock is currently owned by hedge funds and other institutional investors.

CGIX has been the subject of a number of recent analyst reports. Maxim Group set a $6.00 target price on shares of Cancer Genetics and gave the stock a “buy” rating in a research report on Wednesday, December 13th. HC Wainwright set a $6.00 target price on shares of Cancer Genetics and gave the stock a “buy” rating in a research report on Wednesday, November 29th. Zacks Investment Research cut shares of Cancer Genetics from a “hold” rating to a “sell” rating in a research report on Wednesday, October 4th. Finally, ValuEngine cut shares of Cancer Genetics from a “hold” rating to a “sell” rating in a research report on Friday, September 1st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $5.56.

ILLEGAL ACTIVITY WARNING: “John A. Roberts Acquires 12,200 Shares of Cancer Genetics Inc (CGIX) Stock” was published by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this news story on another publication, it was illegally copied and republished in violation of United States & international copyright law. The legal version of this news story can be viewed at https://sportsperspectives.com/2017/12/18/john-a-roberts-acquires-12200-shares-of-cancer-genetics-inc-cgix-stock.html.

Cancer Genetics Company Profile

Cancer Genetics, Inc is a United States-based company, which is engaged in the field of personalized medicine. The Company offers diagnostic products and services that enable precision medicine in the field of oncology through molecular markers and diagnostics. The Company offers a range of laboratory services that provide genomic and biomarker information.

Insider Buying and Selling by Quarter for Cancer Genetics (NASDAQ:CGIX)

Receive News & Ratings for Cancer Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply